LY2886721

LY2886721 selectively inhibits the beta-site amyloid protein cleaving enzyme (BACE) (IC50 = 20 nM for recombinant hBACE1). BACE performs the first cleavage step in the Abeta cascade, thus, its inhibition by LY2886721 decreases production of all forms of the Abeta peptide. A Phase II clinical study for the use of LY2886721 in the treatment of Alzheimer's disease was terminated early due to abnormal liver biochemistry values in several patients. The toxic effects did not appear to be due to BACE inhibition.Formal Name: N-[3-[(4aS,7aS)-2-amino-4a,5-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(7H)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide. CAS Number: 1262036-50-9. Synonyms: beta-Secretase. Molecular Formula: C18H16F2N4O2S. Formula Weight: 390.4. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMSO: 9 mg/ml, Ethanol: <1 mg/ml, Water: <1 mg/ml. lambdamax: 279 nm. SMILES: FC1=CC=C(C(NC2=CC([C@@]34N=C(N)SC[C@]3([H])COC4)=C(F)C=C2)=O)N=C1. InChi Code: InChI=1S/C18H16F2N4O2S/c19-11-1-4-15(22-6-11)16(25)23-12-2-3-14(20)13(5-12)18-9-26-7-10(18)8-27-17(21)24-18/h1-6,10H,7-9H2,(H2,21,24)(H,23,25)/t10-,18-/m0/s1. InChi Key: NIDRNVHMMDAAIK-YPMLDQLKSA-N.